MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:29Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Alpha-1 blockers]]
			[[Category:BPH treatments]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #24

2026-05-23T03:29:43Z

parser-claude batch MedTemplate pre-fill, Top 300 #24

New page

{{MedTemplate
| generic = Tamsulosin
| brand = Flomax
| structure =
| classes = [[:Category:Alpha-1_blockers|Alpha-1A adrenergic blocker]], [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]]
| uses = <vote slug="bph-luts-use">Benign prostatic hyperplasia (LUTS)</vote>, <vote slug="ureteral-stone-passage-use">Medical expulsive therapy for distal ureteral stones</vote>
| starting_dose = 0.4 mg PO once daily, 30 minutes after the same meal each day
| preparations = 0.4 mg capsules
| fda_max = 0.8 mg/d (rarely needed)
| pill_id =
| routes = Oral
| onset = Symptom improvement within 1 week; peak effect at 4-6 weeks
| duration = 24 hours
| halflife = 9-15 hours<ref name="flomax-label">FDA Prescribing Information, Flomax (tamsulosin HCl), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020579s044lbl.pdf</ref>
| bioavailability = >90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)<ref name="flomax-label" />
| pregnancy = Not applicable (male indication); historical Category B if used in unrelated female cases.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="tamsulosin-mech-claim">Tamsulosin selectively antagonizes α1A adrenergic receptors, the dominant subtype in prostatic and bladder-neck smooth muscle, relaxing outflow tract tone and improving urodynamic flow with less peripheral hypotension than non-selective α-blockers.</vote> CYP3A4 and CYP2D6 substrate. The α1A-selective binding underlies '''intraoperative floppy iris syndrome''' (IFIS), a recognized cataract-surgery complication that does not reverse after stopping the drug; preoperative disclosure is standard<ref name="flomax-label" />.
}}

== References ==
<references />

Tamsulosin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #24